Recent VSTM News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:21:41 PM
- Verastem Oncology to Present at Upcoming Investor Conferences • Business Wire • 05/12/2026 11:30:00 AM
- On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer • Business Wire • 05/08/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:11:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:07:25 PM
- Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:01:09 PM
- Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer • Business Wire • 04/30/2026 11:30:00 AM
- Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 • Business Wire • 04/23/2026 11:30:00 AM
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers • Business Wire • 04/10/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:14:51 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 09:20:14 PM
- Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 • Business Wire • 03/17/2026 10:03:00 PM
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers • Business Wire • 03/17/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:15:33 PM
- Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates • Business Wire • 03/04/2026 09:01:00 PM
- Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 • Business Wire • 02/18/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 09:10:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 12:30:33 PM
- Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers • Business Wire • 02/04/2026 12:30:00 PM
- $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors • PR Newswire (Canada) • 01/30/2026 03:19:00 PM
